Please login to the form below

Not currently logged in
Email:
Password:

fistulas

This page shows the latest fistulas news and features for those working in and with pharma, biotech and healthcare.

Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy

Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy

Will treat perianal fistulas in adult patients with Crohn’s disease. Takeda has chalked up a big win this week after receiving a European licence for Alofisel (darvadstrocel), marking the first ... Alofisel - previously Cx601 - is approved to treat

Latest news

  • The power of pharma businesses to drive social change The power of pharma businesses to drive social change

    estimated 3, 000 new cases of obstetric fistula annually, with the problem particularly prevalent in rural communities. ... We are really proud of what we have been able to achieve with the Fistula Foundation.

  • Takeda offers €520m for stem cell firm TiGenix Takeda offers €520m for stem cell firm TiGenix

    Around a quarter of patients with Crohn’s develop fistulas - abnormal channels connecting the bowel to another organ or the outside surface of the body. ... Perianal fistulas are the most common type but are still fairly rare, with patients currently

  • CHMP backs Europe’s first allogeneic stem cell therapy CHMP backs Europe’s first allogeneic stem cell therapy

    Belgian biotech TiGenix and partner Takeda have had their stem cell therapy for perianal fistulas in Crohn’s disease patients recommended for approval in the EU. ... The most common side effects observed include anal abscess and fistula, as well as

  • TiGenix’s Crohn's fistulas treatment wins orphan drug status TiGenix’s Crohn's fistulas treatment wins orphan drug status

    FDA designation follows positive trial results. Belgian biopharmaceutical group TiGenix is one step closer to getting its first-in-class Crohn’s fistulas disease treatment to the US market following an ... The drug - currently known as Cx601 - could

  • TiGenix cell therapy for Crohn's fistulas shows long-term benefit TiGenix cell therapy for Crohn's fistulas shows long-term benefit

    Belgian biotech TiGenix has racked up another positive result for its Takeda-partnered stem cell therapy for fistulas caused by Crohn's disease. ... Results of the phase III ADMIRE-CD trial show that a single administration of Cx601 - a suspension of

More from news
Approximately 4 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    for local administration for the treatment of complex perianal fistulas in patients with Crohn’s disease.  The companies were already partners having signed a $432m licensing deal in July 2016 for ... Option exercise (2 options). 640. TiGenix/Takeda.

  • Case study: Action on Fistula Case study: Action on Fistula

    fistula through building in-country capacity to recognise, treat and eventually eradicate long-term suffering. ... The programme revealed awareness of fistula is very low, even within the healthcare system.

  • Deal Watch July 2016 Deal Watch July 2016

    cells. The product has been submitted to the EMA following a phase III trial showing safety and efficacy of a single injection in the treatment of complex peri-anal fistulas, and ... Acquisition. 416. TiGenix/ Takeda. Cx601 - Stem cell treatment for

More from intelligence
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics